Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based BioLineRx has signed a worldwide exclusive license agreement with Innovative Pharmaceutical Concepts for the development and commercialization of BL-5010, a novel formulation for the non-surgical removal of skin lesions. Financial terms of the license were not disclosed.
Subscribe to our email newsletter
The company said that BL-5010 is a convenient treatment that offers an alternative to painful, invasive and expensive removal treatments such as surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging.
BL-5010 is applied topically on the lesion for a few minutes, and causes the lesion to gradually dry out and shed from the skin within one to three weeks. BL-5010 also preserves the cellular structure of the lesion, enabling histological examination.
Morris Laster, CEO of BioLineRx, said: “BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions. We look forward to accelerating development of this novel formulation.”